BI-505 data at American Society of Hematology

Lund, Sweden – 2 December 2011 – Researchers at the University of Utah, Salt Lake City, under the direction of professor Guido Tricot, will present data involving BI-505 at the annual meeting of American Society of Hematology, which takes place in San Diego, December 10-13, 2011. The abstract will be discussed during an oral session on Sunday, December 11, 2011.

The abstract can be retrieved at www.hematology.org under the Abstract section.
Abstract #2914, The effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells. Session: 652, Myeloma – Pathophysiology and Pre-Clinical Studies. Sunday, December 11, 2011, 6:00 PM-8:00 PM.

A poster will be accessible at the BioInvent home page after the presentation on December 11, 2011.

-- END --

To the editors:

About BI-505
BI-505 is a fully human, monoclonal antibody developed from BioInvent’s proprietary screening platform FIRST™, a function first approach to antibody drug discovery, which in its turn builds on BioInvent’s extensive n-CoDeR® library. BI-505 binds to the cell-surface protein ICAM-1 (Inter-Cellular Adhesion Molecule-1), which has been shown to be overexpressed in multiple myeloma cell lines and primary patient myeloma cells. BioInvent has shown in animal models for multiple myeloma that BI-505 kills tumour cells through induction of both programmed cell death and Fc gamma receptor dependent anti-tumour immunity. BI-505 is currently being investigated in a phase I clinical trial involving approximately 35 patients at clinical centres both in the US and EU.

About multiple myeloma
Multiple myeloma is a type of cancer formed by malignant plasma cells. Normal plasma cells, also called B cells, are mostly found in the bone marrow and are important parts of the innate immune system. It is expected that 20,520 new cases of multiple myeloma will be diagnosed in the US in 2011, making it the second most common haematological cancer. The 5-year relative survival rate is around 40 per cent (www.cancer.org).

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company’s competitive position is underpinned by its patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at www.bioinvent.com.

For further information, please contact:

College Hill (media enquiries)
Melanie Toyne Sewell, Anastasios Koutsos
Tel: +44 (0)20 7866 7856
Rebecca Skye Dietrich
Tel: -1 (857) 241-0795
E-mail: bioinvent@collegehill.com

BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Tel: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

Legal disclaimer
This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 2 December, 2011.

Tags: